Valuation Through A Health Lense & What Professional Investors Look For

What is happening? Webinar about: "Valuation Through A Health Lense & What Professional Investors Look For"

When? 19^h of October, 10:00 – 12:00

Join us for an overview of health focused company valuation methods by a valuation expert with vast health specific experience, followed by a walk-through of the decision-making process used by seasoned investors when they invested early (and subsequently followed-on) in one of Norway’s most successful biotech companies, Vaccibody. We hear from key stakeholders on both sides of the table.

NOTE: Vaccibody just secured the largest Biotech deal Norway has EVER seen

This should be really interesting for both established health investors as well as those wanting to know more about it!

Hope to see you there!

SPEAKERS:

Patrik Frei – Venture Valuations
Dr. Patrik Frei is founder and CEO of Venture Valuation AG, Switzerland, the company he started in 1999 based on collaboration with the Novartis Venture Fund. He has been involved in over 700 valuations around the globe for investors & companies (Biotech, Pharma, Medtech). Patrik has board experience with public and private companies.

Erlend Skagseth – Sarsia Seed
Early stage investor in Vaccibody. 20 years of experience from R&D based IPR, project- and business development from Christian Michelsen Research, Forinnova and Sarsia Innovation. Has managed several turnaround processes and negotiated a large number of international contracts, licenses and trade exits. Broad board experience.

Tom E. Pike – Credio AS
Served as Chairperson of Vaccibody for nearly 11 years and was acting CEO in 2015. Previous positions include General Manger Roche Norway, Partner in the venture capital fund NeoMed, Chairperson & CEO of Clavis Pharma ASA as well as Chairperson of the Association of the Pharmaceutical Industry in Norway.